Skip to main content
Top
Published in: Breast Cancer Research and Treatment 2/2017

Open Access 01-11-2017 | Brief Report

NanoString-based breast cancer risk prediction for women with sclerosing adenosis

Authors: Stacey J. Winham, Christine Mehner, Ethan P. Heinzen, Brendan T. Broderick, Melody Stallings-Mann, Aziza Nassar, Robert A. Vierkant, Tanya L. Hoskin, Ryan D. Frank, Chen Wang, Lori A. Denison, Celine M. Vachon, Marlene H. Frost, Lynn C. Hartmann, E. Aubrey Thompson, Mark E. Sherman, Daniel W. Visscher, Amy C. Degnim, Derek C. Radisky

Published in: Breast Cancer Research and Treatment | Issue 2/2017

Login to get access

Abstract

Purpose

Sclerosing adenosis (SA), found in ¼ of benign breast disease (BBD) biopsies, is a histological feature characterized by lobulocentric proliferation of acini and stromal fibrosis and confers a two-fold increase in breast cancer risk compared to women in the general population. We evaluated a NanoString-based gene expression assay to model breast cancer risk using RNA derived from formalin-fixed, paraffin-embedded (FFPE) biopsies with SA.

Methods

The study group consisted of 151 women diagnosed with SA between 1967 and 2001 within the Mayo BBD cohort, of which 37 subsequently developed cancer within 10 years (cases) and 114 did not (controls). RNA was isolated from benign breast biopsies, and NanoString-based methods were used to assess expression levels of 61 genes, including 35 identified by previous array-based profiling experiments and 26 from biological insight. Diagonal linear discriminant analysis of these data was used to predict cancer within 10 years. Predictive performance was assessed with receiver operating characteristic area under the curve (ROC-AUC) values estimated from 5-fold cross-validation.

Results

Gene expression prediction models achieved cross-validated ROC-AUC estimates ranging from 0.66 to 0.70. Performing univariate associations within each of the five folds consistently identified genes DLK2, EXOC6, KIT, RGS12, and SORBS2 as significant; a model with only these five genes showed cross-validated ROC-AUC of 0.75, which compared favorably to risk prediction using established clinical models (Gail/BCRAT: 0.57; BBD-BC: 0.67).

Conclusions

Our results demonstrate that biomarkers of breast cancer risk can be detected in benign breast tissue years prior to cancer development in women with SA. These markers can be assessed using assay methods optimized for RNA derived from FFPE biopsy tissues which are commonly available.
Appendix
Available only for authorised users
Literature
2.
go back to reference Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ, Visscher DW (2005) Benign breast disease and the risk of breast cancer. N Engl J Med 353(3):229–237. doi:10.1056/NEJMoa044383 CrossRefPubMed Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, Vierkant RA, Maloney SD, Pankratz VS, Hillman DW, Suman VJ, Johnson J, Blake C, Tlsty T, Vachon CM, Melton LJ, Visscher DW (2005) Benign breast disease and the risk of breast cancer. N Engl J Med 353(3):229–237. doi:10.​1056/​NEJMoa044383 CrossRefPubMed
3.
go back to reference Allred DC, Mohsin SK, Fuqua SA (2001) Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 8(1):47–61CrossRefPubMed Allred DC, Mohsin SK, Fuqua SA (2001) Histological and biological evolution of human premalignant breast disease. Endocr Relat Cancer 8(1):47–61CrossRefPubMed
4.
go back to reference Jensen RA, Page DL, Dupont WD, Rogers LW (1989) Invasive breast cancer risk in women with sclerosing adenosis. Cancer 64(10):1977–1983CrossRefPubMed Jensen RA, Page DL, Dupont WD, Rogers LW (1989) Invasive breast cancer risk in women with sclerosing adenosis. Cancer 64(10):1977–1983CrossRefPubMed
6.
go back to reference Degnim AC, Nassar A, Stallings-Mann M, Keith Anderson S, Oberg AL, Vierkant RA, Frank RD, Wang C, Winham SJ, Frost MH, Hartmann LC, Visscher DW, Radisky DC (2015) Gene signature model for breast cancer risk prediction for women with sclerosing adenosis. Breast Cancer Res Treat 152(3):687–694. doi:10.1007/s10549-015-3513-1 CrossRefPubMedPubMedCentral Degnim AC, Nassar A, Stallings-Mann M, Keith Anderson S, Oberg AL, Vierkant RA, Frank RD, Wang C, Winham SJ, Frost MH, Hartmann LC, Visscher DW, Radisky DC (2015) Gene signature model for breast cancer risk prediction for women with sclerosing adenosis. Breast Cancer Res Treat 152(3):687–694. doi:10.​1007/​s10549-015-3513-1 CrossRefPubMedPubMedCentral
7.
go back to reference Milanese TR, Hartmann LC, Sellers TA, Frost MH, Vierkant RA, Maloney SD, Pankratz VS, Degnim AC, Vachon CM, Reynolds CA, Thompson RA, Melton LJ 3rd, Goode EL, Visscher DW (2006) Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst 98(22):1600–1607. doi:10.1093/jnci/djj439 CrossRefPubMed Milanese TR, Hartmann LC, Sellers TA, Frost MH, Vierkant RA, Maloney SD, Pankratz VS, Degnim AC, Vachon CM, Reynolds CA, Thompson RA, Melton LJ 3rd, Goode EL, Visscher DW (2006) Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst 98(22):1600–1607. doi:10.​1093/​jnci/​djj439 CrossRefPubMed
8.
go back to reference Nueda ML, Naranjo AI, Baladron V (1843) Laborda J (2014) The proteins DLK1 and DLK2 modulate NOTCH1-dependent proliferation and oncogenic potential of human SK-MEL-2 melanoma cells. Biochim Biophys Acta 11:2674–2684. doi:10.1016/j.bbamcr.2014.07.015 Nueda ML, Naranjo AI, Baladron V (1843) Laborda J (2014) The proteins DLK1 and DLK2 modulate NOTCH1-dependent proliferation and oncogenic potential of human SK-MEL-2 melanoma cells. Biochim Biophys Acta 11:2674–2684. doi:10.​1016/​j.​bbamcr.​2014.​07.​015
11.
go back to reference Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16):5367–5374. doi:10.1158/1078-0432.CCR-04-0220 CrossRefPubMed Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM (2004) Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 10(16):5367–5374. doi:10.​1158/​1078-0432.​CCR-04-0220 CrossRefPubMed
12.
go back to reference Alsafadi S, Scott V, Pautier P, Goubar A, Lazar V, Dessen P, Lacroix L, Duvillard P, Morice P, Andre F, Delaloge S (2011) Identification of SORBS2 as a candidate marker to predict metastatic relapse in breast cancer. Cancer Res. doi:10.1158/0008-5472.SABCS11-P5-01-07 Alsafadi S, Scott V, Pautier P, Goubar A, Lazar V, Dessen P, Lacroix L, Duvillard P, Morice P, Andre F, Delaloge S (2011) Identification of SORBS2 as a candidate marker to predict metastatic relapse in breast cancer. Cancer Res. doi:10.​1158/​0008-5472.​SABCS11-P5-01-07
13.
go back to reference Chang H, Jeung HC, Jung JJ, Kim TS, Rha SY, Chung HC (2011) Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells. Breast Cancer Res Treat 125(1):55–63. doi:10.1007/s10549-010-0825-z CrossRefPubMed Chang H, Jeung HC, Jung JJ, Kim TS, Rha SY, Chung HC (2011) Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells. Breast Cancer Res Treat 125(1):55–63. doi:10.​1007/​s10549-010-0825-z CrossRefPubMed
15.
go back to reference Smeets A, Daemen A, Vanden Bempt I, Gevaert O, Claes B, Wildiers H, Drijkoningen R, Van Hummelen P, Lambrechts D, De Moor B, Neven P, Sotiriou C, Vandorpe T, Paridaens R, Christiaens MR (2011) Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAs. Breast Cancer Res Treat 129(3):767–776. doi:10.1007/s10549-010-1265-5 CrossRefPubMed Smeets A, Daemen A, Vanden Bempt I, Gevaert O, Claes B, Wildiers H, Drijkoningen R, Van Hummelen P, Lambrechts D, De Moor B, Neven P, Sotiriou C, Vandorpe T, Paridaens R, Christiaens MR (2011) Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAs. Breast Cancer Res Treat 129(3):767–776. doi:10.​1007/​s10549-010-1265-5 CrossRefPubMed
17.
go back to reference Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA (2001) Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 93(5):358–366CrossRefPubMed Rockhill B, Spiegelman D, Byrne C, Hunter DJ, Colditz GA (2001) Validation of the Gail et al. model of breast cancer risk prediction and implications for chemoprevention. J Natl Cancer Inst 93(5):358–366CrossRefPubMed
18.
19.
go back to reference Nassar A, Hoskin TL, Stallings-Mann ML, Degnim AC, Radisky DC, Frost MH, Vierkant RA, Hartmann LC, Visscher DW (2015) Ki-67 expression in sclerosing adenosis and adjacent normal breast terminal ductal lobular units: a nested case-control study from the Mayo Benign Breast Disease Cohort. Breast Cancer Res Treat 151(1):89–97. doi:10.1007/s10549-015-3370-y CrossRefPubMedPubMedCentral Nassar A, Hoskin TL, Stallings-Mann ML, Degnim AC, Radisky DC, Frost MH, Vierkant RA, Hartmann LC, Visscher DW (2015) Ki-67 expression in sclerosing adenosis and adjacent normal breast terminal ductal lobular units: a nested case-control study from the Mayo Benign Breast Disease Cohort. Breast Cancer Res Treat 151(1):89–97. doi:10.​1007/​s10549-015-3370-y CrossRefPubMedPubMedCentral
20.
go back to reference Barr FE, Degnim AC, Hartmann LC, Radisky DC, Boughey JC, Anderson SS, Vierkant RA, Frost MH, Visscher DW, Reynolds C (2011) Estrogen receptor expression in atypical hyperplasia: lack of association with breast cancer. Cancer Prev Res (Phila) 4(3):435–444. doi:10.1158/1940-6207.CAPR-10-0242 CrossRef Barr FE, Degnim AC, Hartmann LC, Radisky DC, Boughey JC, Anderson SS, Vierkant RA, Frost MH, Visscher DW, Reynolds C (2011) Estrogen receptor expression in atypical hyperplasia: lack of association with breast cancer. Cancer Prev Res (Phila) 4(3):435–444. doi:10.​1158/​1940-6207.​CAPR-10-0242 CrossRef
21.
go back to reference Degnim AC, Dupont WD, Radisky DC, Vierkant RA, Frank RD, Frost MH, Winham SJ, Sanders ME, Smith JR, Page DL, Hoskin TL, Vachon CM, Ghosh K, Hieken TJ, Denison LA, Carter JM, Hartmann LC, Visscher DW (2016) Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women. Cancer 122(19):2971–2978. doi:10.1002/cncr.30153 CrossRefPubMedPubMedCentral Degnim AC, Dupont WD, Radisky DC, Vierkant RA, Frank RD, Frost MH, Winham SJ, Sanders ME, Smith JR, Page DL, Hoskin TL, Vachon CM, Ghosh K, Hieken TJ, Denison LA, Carter JM, Hartmann LC, Visscher DW (2016) Extent of atypical hyperplasia stratifies breast cancer risk in 2 independent cohorts of women. Cancer 122(19):2971–2978. doi:10.​1002/​cncr.​30153 CrossRefPubMedPubMedCentral
22.
go back to reference Hieken TJ, Carter JM, Hawse JR, Hoskin TL, Bois M, Frost M, Hartmann LC, Radisky DC, Visscher DW, Degnim AC (2015) ERbeta expression and breast cancer risk prediction for women with atypias. Cancer Prev Res (Phila) 8(11):1084–1092. doi:10.1158/1940-6207.CAPR-15-0198 CrossRef Hieken TJ, Carter JM, Hawse JR, Hoskin TL, Bois M, Frost M, Hartmann LC, Radisky DC, Visscher DW, Degnim AC (2015) ERbeta expression and breast cancer risk prediction for women with atypias. Cancer Prev Res (Phila) 8(11):1084–1092. doi:10.​1158/​1940-6207.​CAPR-15-0198 CrossRef
23.
go back to reference Radisky DC, Santisteban M, Berman HK, Gauthier ML, Frost MH, Reynolds CA, Vierkant RA, Pankratz VS, Visscher DW, Tlsty TD, Hartmann LC (2011) p16(INK4a) expression and breast cancer risk in women with atypical hyperplasia. Cancer Prev Res (Phila) 4(12):1953–1960. doi:10.1158/1940-6207.CAPR-11-0282 CrossRef Radisky DC, Santisteban M, Berman HK, Gauthier ML, Frost MH, Reynolds CA, Vierkant RA, Pankratz VS, Visscher DW, Tlsty TD, Hartmann LC (2011) p16(INK4a) expression and breast cancer risk in women with atypical hyperplasia. Cancer Prev Res (Phila) 4(12):1953–1960. doi:10.​1158/​1940-6207.​CAPR-11-0282 CrossRef
24.
go back to reference Radisky DC, Visscher DW, Frank RD, Vierkant RA, Winham S, Stallings-Mann M, Hoskin TL, Nassar A, Vachon CM, Denison LA, Hartmann LC, Frost MH, Degnim AC (2016) Natural history of age-related lobular involution and impact on breast cancer risk. Breast Cancer Res Treat 155(3):423–430. doi:10.1007/s10549-016-3691-5 CrossRefPubMedPubMedCentral Radisky DC, Visscher DW, Frank RD, Vierkant RA, Winham S, Stallings-Mann M, Hoskin TL, Nassar A, Vachon CM, Denison LA, Hartmann LC, Frost MH, Degnim AC (2016) Natural history of age-related lobular involution and impact on breast cancer risk. Breast Cancer Res Treat 155(3):423–430. doi:10.​1007/​s10549-016-3691-5 CrossRefPubMedPubMedCentral
25.
go back to reference Visscher DW, Pankratz VS, Santisteban M, Reynolds C, Ristimaki A, Vierkant RA, Lingle WL, Frost MH, Hartmann LC (2008) Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. J Natl Cancer Inst 100(6):421–427. doi:10.1093/jnci/djn036 CrossRefPubMed Visscher DW, Pankratz VS, Santisteban M, Reynolds C, Ristimaki A, Vierkant RA, Lingle WL, Frost MH, Hartmann LC (2008) Association between cyclooxygenase-2 expression in atypical hyperplasia and risk of breast cancer. J Natl Cancer Inst 100(6):421–427. doi:10.​1093/​jnci/​djn036 CrossRefPubMed
27.
go back to reference Richard AC, Lyons PA, Peters JE, Biasci D, Flint SM, Lee JC, McKinney EF, Siegel RM, Smith KG (2014) Comparison of gene expression microarray data with count-based RNA measurements informs microarray interpretation. BMC Genom 15:649. doi:10.1186/1471-2164-15-649 CrossRef Richard AC, Lyons PA, Peters JE, Biasci D, Flint SM, Lee JC, McKinney EF, Siegel RM, Smith KG (2014) Comparison of gene expression microarray data with count-based RNA measurements informs microarray interpretation. BMC Genom 15:649. doi:10.​1186/​1471-2164-15-649 CrossRef
Metadata
Title
NanoString-based breast cancer risk prediction for women with sclerosing adenosis
Authors
Stacey J. Winham
Christine Mehner
Ethan P. Heinzen
Brendan T. Broderick
Melody Stallings-Mann
Aziza Nassar
Robert A. Vierkant
Tanya L. Hoskin
Ryan D. Frank
Chen Wang
Lori A. Denison
Celine M. Vachon
Marlene H. Frost
Lynn C. Hartmann
E. Aubrey Thompson
Mark E. Sherman
Daniel W. Visscher
Amy C. Degnim
Derek C. Radisky
Publication date
01-11-2017
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2017
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-017-4441-z

Other articles of this Issue 2/2017

Breast Cancer Research and Treatment 2/2017 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine